Here are five details:
1. A preliminary report estimates the company’s fourth quarter revenue will range between $37.6 million and $38 million, representing a 10.6 percent to 11.8 percent increase year over year.
2. U.S. revenue in the fourth quarter is projected to range between $33.8 million and $34.1 million, an 8 percent to 9 percent increase year over year.
3. SeaSpine’s orthobiologics revenues are anticipated to reflect a 9 percent to 10 percent increase year over year. Similarly, the company’s U.S. spinal implants revenues are expected to increase between 7.5 percent to 8.5 percent for the fourth quarter.
4. SeaSpine’s full-year revenue is estimated to range between $143 million to $143.4 million, representing an 8.5 percent to 9 percent increase year over year.
5. In 2019, the company expects revenue to range between $152 million and $156 million.
More articles on devices and implants:
The Ohio State medical center completes surgery with Calypso Knee System: 3 notes
WishBone Medical responds to OrthoPediatrics’ trade secret allegations
Stryker organic sales growth increases for 6 years, hits 6.4% by 2018 Q3
